Mutation analysis focused on the two genes most commonly mutated in our cohort (KRAS, TP53) and the EGFR gene, i.e. the sole—among genes guiding treatment decision in lung cancer patients [3, 4]—being mutated in the analysed cases. This evidence concerns the gene TP53 and lung carcinoma.